E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003946 |
E.1.2 | Term | B-Lymphocytic, CLL (Kiel Classification) |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10041152 |
E.1.2 | Term | Small lymphocytic lymphoma, consistent with CLL (Working Formulation) |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare efficacy between treatment groups in cohort 1, as measured by progression-free survival determined by independent central review |
|
E.2.2 | Secondary objectives of the trial |
To evaluate efficacy in cohort 1, as measured by the following:
o Overall response rate determined by independent central review and by investigator assessment
o Overall survival
o Duration of response determined by independent central review and by investigator assessment
o Progression-free survival determined by investigator assessment
o Patient-reported outcomes
• To evaluate efficacy in cohort 2 (patients with del[17p]), as measured by the following:
o Overall response rate determined by independent central review
o Overall survival
o Progression-free survival determined by independent central review
o Duration of response determined by independent central review
• To compare safety between the treatment groups in cohort 1
• To evaluate pharmacokinetics of BGB-3111 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Unsuitable for chemoimmunotherapy with FCR in the opinion of the investigator
2. Confirmed diagnosis of CD20-positive CLL or SLL that meets the CLL criteria (Hallek et al, 2008)
3. Binet Stage C disease, or Binet Stage B or A disease requiring treatment as defined by at least one of the criteria (Hallek et al, 2008)
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
5. Life expectancy ≥ 6 months
6. Adequate bone marrow function
7. Patient must have adequate organ function
8. Female patients of childbearing potential must practice highly effective methods of contraception initiated prior to first dose of study drug, for the duration of the study, and for ≥ 90 days after the last dose of BGB-3111, 3 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer.
9. Male patients are eligible if vasectomized or if they agree to the use of barrier contraception with other methods described above during the study treatment period and for ≥ 90 days after the last dose of BGB-3111 or 3 months after the last dose of bendamustine whichever is longer.
10. Ability to provide written informed consent and can understand and comply with the requirements of the study |
|
E.4 | Principal exclusion criteria |
1. Previous systemic treatment for CLL/SLL
2. Known prolymphocytic leukemia or history of, or currently suspected, Richter’s transformation
3. Clinically significant cardiovascular disease
4. Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast
5. History of severe bleeding disorder
6. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
7. Severe or debilitating pulmonary disease
8. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
9. Active fungal, bacterial and/or viral infection requiring systemic therapy
10. Known central nervous system involvement by leukemia or lymphoma
11. Underlying medical conditions that, in the investigator’s opinion, will render the administration of study drug hazardous or obscure the interpretation of toxicity or AEs
12. Known infection with HIV, or serologic status reflecting active hepatitis B or C infection
13. Major surgery within 4 weeks of the first dose of study drug
14. Pregnant or lactating women
15. Vaccination with a live vaccine within 35 days prior to the first dose of study drug
16. Ongoing alcohol or drug addiction
17. Hypersensitivity to BGB-3111, bendamustine, or rituximab or any of the other ingredients of the study drugs
18. Requires ongoing treatment with a strong CYP3A inhibitor or inducer
19. Concurrent participation in another therapeutic clinical trial. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is progression-free survival in cohort 1 (patients without del[17p]) determined by independent central review using the iwCLL guidelines with modification for treatment-related lymphocytosis, and defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1 interim analysis of progression-free survival by independent central review in cohort 1, performed when approximately 79 events (67% of the target number of events at final analysis) from the arms A and B are observed. It is estimated that it will take approximately 25 months to observe 79 events. The final analysis of progression-free survival will take place after 118 events are observed, which is estimated as approximately 35 months from study start.
|
|
E.5.2 | Secondary end point(s) |
• Overall response rate in cohort 1 defined as the proportion of patients who achieve a complete response, complete response with incomplete bone marrow recovery, partial response, or partial response with lymphocytosis, determined by independent central review and by investigator assessment
• Overall survival in cohort 1 defined as the time from randomization to the date of death due to any reason
• Duration of response in cohort 1 determined by independent central review and by investigator assessment using the iwCLL criteria with modification for treatment-related lymphocytosis, and defined as the time from the date that response criteria are first met to the date that disease progression is objectively documented or death, whichever occurs first
• Progression-free survival in cohort 1 determined by investigator assessment
• Patient-reported outcomes in cohort 1 measured by the EQ-5D-5L and EORTC QLQ-C30 questionnaires
• Overall response rate in cohort 2 (patients with del[17p]) determined by independent central review
• Overall survival in cohort 2
• Progression-free survival in cohort 2 determined by independent central review
• Duration of response in cohort 2 determined by independent central review
• Safety parameters, including AEs, SAEs, clinical laboratory tests, physical exams, and vital signs
• Pharmacokinetic parameters such as apparent clearance of the drug from plasma (CL/F) and AUC0-12 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At time of interim analysis if the PFS comparison between the 2 arms in cohort 1 crosses the stopping boundary. Or at the time of final PFS analysis. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 90 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Austria |
Belgium |
Canada |
Czech Republic |
France |
Germany |
Hungary |
Israel |
Italy |
Korea, Republic of |
Netherlands |
New Zealand |
Poland |
Russian Federation |
Spain |
Sweden |
Taiwan |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |